Study Group: Zocor Prescribers
Council Members in this Study Group: 72
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Contact Gerson Lehrman Group to survey or consult with members of this Study Group
Leading institutions connect with members of this Study Group through GLG
Leading Experts in this Study Group
Harold BaysPresident and Medical Director
L-MARC Research Center
Harold Bays, MD, FACP, FACE, is Medical Director and President of Louisville Metabolic and Atherosclerosis Research Center (L-MARC), a metabolic clinical research facility that has conducted over 400 phase I-IV clinical trials, including studies of all...
- Mark Feinberg
Assistant Professor
HARVARD MEDICAL SCHOOLMark Feinberg, MD, is an Associate Physician and Principal Investigator in the Cardiovascular Division at Brigham and Women's Hospital and an Assistant Professor of Medicine at Harvard Medical School, Massachusetts. He has expertise in the management...
Hossein ArdehaliAssistant Professor
Northwestern University, Feinberg School of MedicineHossein Ardehali, MD, PhD, is Assistant Professor of Medicine at Feinberg Cardiovascular Institute in Illinois. His specialties include lipid metabolism, preventive cardiology, electrophysiology and heart failure. Dr. Ardehali's basic science research...
- Daniel Fisher
Cardiologist
NEW YORK UNIVERSITY (INC)Daniel Fisher, MD, FACC, FACP, is a Cardiologist at NYU Medical Center. He has a private practice in Cardiology and specializes in non-invasive cardiology. Dr. Fisher is board certified in Internal Medicine, Cardiovascular Diseases, and Nuclear Cardiology....
Rohit AroraProfessor of Medicine
Finch University of Health Science-Chicago Medical SchoolRohit Arora, MD, FACC, FAHA, FASCI, FACP, is Professor of Medicine and Professor of Physiology and Biophysics at Chicago Medical School. He is also the Chairman of Cardiology and Associate Chairman of Medicine in the Department of Medicine. Previously,...
GLG NewsSM Analyses by this Study Group's Leading Experts(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
September 30, 2009
Controls to blood sugar 'cuts stroke risk' | www.barchester.com
There have been many epidemiologic studies showing a very tight correlation between baseline A1c and cardiovascular mortalityDespite this, five major randomized prospective studies have failed to show any macrovascular benefit for tighter glucose controlThe logical conclusion is that glucose is, therefore, a marker for increased mortality but not a modifiable risk factor thereofThis is why FDA has mandated cardiovascular safety for new antidiabetic agentsData dredging persists, however
-
If it seems too good to be true...it probably is.
December 9, 2008
Analysis by: Joshua Feuer, Owner,Generic Heart Drugs as Good as Brand-Name Counterparts | www.washingtonpost.com
This article implies that physician's have no justifiable reason for prescribing brand-name drugs. Unfortunately, it's not that simple.
-
December 8, 2008
Analysis by: Joshua Feuer, Owner,There is a question of bias in this study. It is not prospective, not randomized and not blinded and thus no valid conclusions can be made. The study should be ignored. It will have no impact on sales.
-
Tamper Proof Narcotic Pain pill? YES
November 13, 2008
Analysis by: David Zimmerman, President/Owner,FDA Asks if Pain Pill Is Tamper-Proof | online.wsj.com
This drug will allow patients in severe pain to get the necessary pain relief and not have to worry about the other patients that abuse the drug.
-
November 13, 2008
CRESTOR Demonstrates Dramatic CV Risk Reduction in a Large Statin Outcomes Study | www.astrazeneca.com
1:Crestor is the most potent statin in the market,yet is 3d in sales behind Zocor and Lipitor.2:The efficacy supriority together with its capacity to lower CRP levels led to the highest rate of ASCVD prevention in the shortest period of time evr documented in statin trials.3:The trial in near 18,000 patients with otherwise lower risk of ASCVD offered $0% reduction y many ascvd endpoints.4:There were no statistical differences in side effect compared to placebo.5:The dosage was 20 mg /day (an intermediate dose below the approved max dose of 40 mg/day
Members in this Study Group include these company types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Non-Academic Community Hospital or Clinic
- Contract Research Organization, Independent/Small
- Government/Military Hospital or Clinic
Members in this Study Group often have these job titles:
- Physician - Attending Physician
- Physician - Director
- Owner
- Director
- Physician - Division Head
- Partner
Related Study Groups
GLG Live Meetings with this Study Group's Leading Experts (?)
May 22, 2008 | Boston
GLG Seminar: Diabetes and ObesityMarch 28, 2008 | Boston
GLGi: Lipid ManagementJune 20, 2007 | Chicago
GLGi: Diabetes and ObesityGLG Webcasts & Teleconferences
Leading Experts in Zocor Prescribers have not participated in any GLG webcasts.